<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436111</url>
  </required_header>
  <id_info>
    <org_study_id>KK-2007-1</org_study_id>
    <nct_id>NCT00436111</nct_id>
  </id_info>
  <brief_title>Characterization of Macroprolactinemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansai Medical University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to clarify the nature of macroprolactin which has recently been
      highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia.
      The results of this study are beneficial for the patients to whom unnecessary medications and
      unnecessary radiological examinations have been performed.

      We used the remained serum samples taken for routine prolactin determination during the past
      several years. Since the blood was basically taken to examine the causes of
      hyperprolactinemia and only remained serum samples were used for this study, the Ethics
      Committee of Kobe City General Hospital judged that it was not required to obtain approval
      number.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date>December 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Retrospective</time_perspective>
  </study_design_info>
  <condition>Hyperprolactinemia</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of hyperprolactinemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Naoki Hattori, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pharmacology, Kansai Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansai Medical University</name>
      <address>
        <city>Osaka</city>
        <zip>570-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Hattori N, Nakayama Y, Kitagawa K, Ishihara T, Saiki Y, Inagaki C. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol. 2006 Aug;190(2):287-93.</citation>
    <PMID>16899562</PMID>
  </results_reference>
  <results_reference>
    <citation>Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab. 2005 May;90(5):3036-44. Epub 2005 Feb 1.</citation>
    <PMID>15687336</PMID>
  </results_reference>
  <results_reference>
    <citation>Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab. 1997 Sep;82(9):3107-10.</citation>
    <PMID>9284753</PMID>
  </results_reference>
  <results_reference>
    <citation>Hattori N, Ishihara T, Ikekubo K, Moridera K, Hino M, Kurahachi H. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9.</citation>
    <PMID>1430082</PMID>
  </results_reference>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2007</study_first_posted>
  <last_update_submitted>February 15, 2007</last_update_submitted>
  <last_update_submitted_qc>February 15, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2007</last_update_posted>
  <keyword>hyperprolactinemia</keyword>
  <keyword>autoantibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperprolactinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

